791 related articles for article (PubMed ID: 27063854)
1. Mirabegron as Add-On Treatment to Solifenacin in Patients with Incontinent Overactive Bladder and an Inadequate Response to Solifenacin Monotherapy: Responder Analyses and Patient-Reported Outcomes from the BESIDE Study [corrected].
MacDiarmid S; Al-Shukri S; Barkin J; Fianu-Jonasson A; Grise P; Herschorn S; Saleem T; Huang M; Siddiqui E; Stölzel M; Hemsted C; Nazir J; Hakimi Z; Drake MJ;
J Urol; 2016 Sep; 196(3):809-18. PubMed ID: 27063854
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study).
Herschorn S; Chapple CR; Abrams P; Arlandis S; Mitcheson D; Lee KS; Ridder A; Stoelzel M; Paireddy A; van Maanen R; Robinson D
BJU Int; 2017 Oct; 120(4):562-575. PubMed ID: 28418102
[TBL] [Abstract][Full Text] [Related]
3. Treating Overactive Bladder in Older Patients with a Combination of Mirabegron and Solifenacin: A Prespecified Analysis from the BESIDE Study.
Gibson W; MacDiarmid S; Huang M; Siddiqui E; Stölzel M; Choudhury N; Drake MJ
Eur Urol Focus; 2017 Dec; 3(6):629-638. PubMed ID: 28916436
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE).
Drake MJ; Chapple C; Esen AA; Athanasiou S; Cambronero J; Mitcheson D; Herschorn S; Saleem T; Huang M; Siddiqui E; Stölzel M; Herholdt C; MacDiarmid S;
Eur Urol; 2016 Jul; 70(1):136-145. PubMed ID: 26965560
[TBL] [Abstract][Full Text] [Related]
5. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, Phase II study (SYMPHONY).
Abrams P; Kelleher C; Staskin D; Kay R; Martan A; Mincik I; Newgreen D; Ridder A; Paireddy A; van Maanen R
World J Urol; 2017 May; 35(5):827-838. PubMed ID: 27514371
[TBL] [Abstract][Full Text] [Related]
6. Long-term safety and efficacy of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A multicenter, randomized study in Japan (MILAI II study).
Yamaguchi O; Kakizaki H; Homma Y; Igawa Y; Takeda M; Nishizawa O; Gotoh M; Yoshida M; Yokoyama O; Seki N; Okitsu A; Hamada T; Kobayashi A; Kuroishi K
Int J Urol; 2019 Mar; 26(3):342-352. PubMed ID: 30548692
[TBL] [Abstract][Full Text] [Related]
7. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).
Abrams P; Kelleher C; Staskin D; Rechberger T; Kay R; Martina R; Newgreen D; Paireddy A; van Maanen R; Ridder A
Eur Urol; 2015 Mar; 67(3):577-88. PubMed ID: 24612659
[TBL] [Abstract][Full Text] [Related]
8. Patient-reported outcomes from SYNERGY, a randomized, double-blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with monotherapy and placebo in OAB patients.
Robinson D; Kelleher C; Staskin D; Mueller ER; Falconer C; Wang J; Ridder A; Stoelzel M; Paireddy A; van Maanen R; Hakimi Z; Herschorn S
Neurourol Urodyn; 2018 Jan; 37(1):394-406. PubMed ID: 28704584
[TBL] [Abstract][Full Text] [Related]
9. Long-term Safety and Efficacy of Mirabegron and Solifenacin in Combination Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II).
Gratzke C; van Maanen R; Chapple C; Abrams P; Herschorn S; Robinson D; Ridder A; Stoelzel M; Paireddy A; Yoon SJ; Al-Shukri S; Rechberger T; Mueller ER
Eur Urol; 2018 Oct; 74(4):501-509. PubMed ID: 29866467
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study).
Yamaguchi O; Kakizaki H; Homma Y; Igawa Y; Takeda M; Nishizawa O; Gotoh M; Yoshida M; Yokoyama O; Seki N; Okitsu A; Hamada T; Kobayashi A; Kuroishi K
BJU Int; 2015 Oct; 116(4):612-22. PubMed ID: 25639296
[TBL] [Abstract][Full Text] [Related]
11. Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER).
Herschorn S; Staskin D; Tu LM; Fialkov J; Walsh T; Gooch K; Schermer CR
Health Qual Life Outcomes; 2018 Apr; 16(1):69. PubMed ID: 29673355
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of mirabegron in female patients with overactive bladder symptoms after surgical treatment for stress urinary incontinence.
Özkidik M; Coşkun A; Asutay MK; Bahçeci T; Hamidi N
Int Braz J Urol; 2019; 45(4):782-789. PubMed ID: 31136113
[TBL] [Abstract][Full Text] [Related]
13. Assessing Preference-Based Outcome Measures for Overactive Bladder: An Evaluation of Patient-Reported Outcome Data from the BESIDE Clinical Trial.
Herdman M; Nazir J; Hakimi Z; Siddiqui E; Huang M; Pavesi M; MacDiarmid S; Drake MJ; Devlin N
Patient; 2017 Dec; 10(6):677-686. PubMed ID: 28646416
[TBL] [Abstract][Full Text] [Related]
14. A randomized, controlled trial of effectiveness and safety of management of OAB symptoms in elderly men and women with standard-dosed combination of solifenacin and mirabegron.
Kosilov K; Loparev S; Ivanovskaya M; Kosilova L
Arch Gerontol Geriatr; 2015; 61(2):212-6. PubMed ID: 26169181
[TBL] [Abstract][Full Text] [Related]
15. Combined treatment of solifenacin and mirabegron, an alternative in patients with overactive bladder (BESIDE study).
Alcántara-Montero A
Actas Urol Esp; 2016 Nov; 40(9):593-594. PubMed ID: 27126125
[No Abstract] [Full Text] [Related]
16. Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes.
Garely AD; Lucente V; Vapnek J; Smith N
Ann Pharmacother; 2007 Mar; 41(3):391-8. PubMed ID: 17341526
[TBL] [Abstract][Full Text] [Related]
17. Patient-reported outcomes with the β
Khullar V; Amarenco G; Angulo JC; Blauwet MB; Nazir J; Odeyemi IA; Hakimi Z
Neurourol Urodyn; 2016 Nov; 35(8):987-994. PubMed ID: 26288118
[TBL] [Abstract][Full Text] [Related]
18. Additional low-dose antimuscarinics can improve overactive bladder symptoms in patients with suboptimal response to beta 3 agonist monotherapy.
Shin JH; Kim A; Choo MS
Investig Clin Urol; 2017 Jul; 58(4):261-266. PubMed ID: 28681036
[TBL] [Abstract][Full Text] [Related]
19. Impact of solifenacin on diary-recorded and patient-reported urgency in patients with severe overactive bladder (OAB) symptoms.
Serels SR; Toglia MR; Forero-Schwanhaeuser S; He W
Curr Med Res Opin; 2010 Oct; 26(10):2277-85. PubMed ID: 20707767
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of treatment with mirabegron compared with solifenacin in the management of overactive bladder syndrome: A retrospective analysis.
Schiavi MC; Faiano P; D'Oria O; Zullo MA; Muzii L; Benedetti Panici P
J Obstet Gynaecol Res; 2018 Mar; 44(3):524-531. PubMed ID: 29271106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
